C9ORF72 in Motor System Biology and ALS
C9ORF72 in Motor System Biology and ALS
批准号:
9292392
负责人:
KEVIN C EGGAN
金额:
$45.42万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-15 至 2019-06-30
关键词:
AdultAllelesAmyotrophic Lateral SclerosisAnimal ModelAnimalsBiological AssayBiologyC9ORF72CellsCessation of lifeCohort AnalysisComb animal structureControl AnimalCre-LoxPDataDenervationDevelopmentDoseFundingGene TargetingGenerationsGenesGenetic TranscriptionImmuneKnock-inKnock-outMaintenanceModelingMotorMotor NeuronsMusMuscular AtrophyMutationNatural HistoryNerve DegenerationNeurodegenerative DisordersOrthologous GeneParalysedPathologyPatientsPhenotypePlayPreparationRodent ModelRoleSamplingSeriesStudy modelsSystemSystems BiologyTechniquesTechnologyTestingTherapeutic Interventionagedastrogliosiscell typedesigndrug discoverygain of functiongene productgenome editinginduced pluripotent stem cellinsightknockout animalloss of functionloss of function mutationmortalitymotor neuron degenerationmouse modelmutantprofiles in patientspublic health relevance
中文摘要
描述(由申请人提供):最近在肌萎缩侧索硬化症(ALS)患者中发现了C9ORF72处的六核苷酸重复扩增。然而,这种突变是通过功能获得机制还是功能丧失机制发挥作用仍有待确定。解决这个问题对于设计和实施抵消ALS这种突变影响的疗法的长期努力至关重要。作为初步数据,我们提供的证据表明,携带C9ORF72直系同源基因功能突变缺失的杂合子和纯合子小鼠是可行的,可以存活到成年,最初表现出与野生型小鼠类似的运动系统功能。然而,随着杂合子动物年龄的增长,我们发现它们的死亡率显著增加。杂合子动物的死亡与运动功能下降和瘫痪有关,并伴随着肌肉萎缩、失神经和运动神经退化。纯合子突变的动物表现出相似的但加速的和数量上更严重的表型。我们的初步研究表明,C9ORF72在哺乳动物运动系统的长期维持中发挥着重要的剂量依赖功能。这些发现支持这样一种假设,即C9ORF72功能降低和许多患者重复扩增导致的单倍体不足直接导致ALS的发展。在这里,我们提出三个目标,以增加对C9ORF72在运动神经元变性生物学中所起作用的理解。首先,我们将确定在C9ORF72正基因突变中存在功能缺失突变的小鼠的运动神经元变性特征与ALS中观察到的特征一致的程度。这些研究将使我们能够确定我们培育的小鼠在多大程度上可以作为机械和药物发现研究的小鼠模型。其次,我们将确定C9ORF72基因突变动物的运动神经元变性是通过运动神经元的细胞自主机制发生的,还是由于突变免疫细胞的非自主影响所致。第三,我们将确定C9ORF72重复扩增在患者来源的运动神经元中发现的转录变化在多大程度上可以用C9ORF72基因产物的功能丧失来解释。如果得到资助,我们的研究将为C9ORF72基因产物丢失在多大程度上导致运动神经元退化提供重要的见解。
英文摘要
DESCRIPTION (provided by applicant): A hexanucleotide repeat expansion at C9ORF72 has recently been found in a significant fraction of patients suffering from Amyotrophic Lateral Sclerosis (ALS). However, it remains to be determined whether this mutation acts through a gain of function or loss of function mechanism. Resolving this issue is essential for long term efforts to design and implement therapies that counteract the effects of this mutation in ALS. As preliminary data, we provide evidence that heterozygous and homozygous mice harboring a loss of function mutation in the ortholog of C9ORF72 are viable, survive to adulthood and initially display motor system functionality similar to their wild type littermates. However, as heterozygous animals aged, we found they displayed a significantly increased rate of mortality. Death in heterozygous animals was associated with declining motor function and paralysis that were accompanied by muscle atrophy, denervation and motor nerve degeneration. Homozygous mutant animals displayed a similar but accelerated and quantitatively more severe phenotype. Our preliminary studies suggest that C9ORF72 serves an important dose dependent function in the long-term maintenance of the mammalian motor system. These findings support the hypothesis that reduced C9ORF72 function and haploinsufficiency resulting from the repeat expansion that many patients harbor contributes directly to the development of ALS. Here we propose three aims to increase understanding of the role that C9ORF72 plays in the biology of motor neuron degeneration. First, we will determine the extent to which features of motor neuron degeneration in mice harboring a loss of function mutation in the C9ORF72 ortholog are consistent with those observed in ALS. These studies will allow us to determine to what extent the mice we have generated might have utility as a mouse model for both mechanistic and drug discovery studies. Second, we will determine whether motor neuron degeneration in C9ORF72 ortholog mutant animals occurs through cell autonomous mechanisms in motor neurons, or is due to the non-autonomous influence of mutant immune cells. Third, we will determine the extent to which transcriptional changes found in patient derived motor neurons by the C9ORF72 repeat expansion can be explained by loss of function of the C9ORF72 gene product. If funded, our studies will provide important insight into the extent to which loss of the C9ORF72 gene product contributes to motor neuron degeneration.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
C9ORF72 in Motor System Biology and ALS
-
批准号:8925168
-
项目类别:
-
资助金额:$43.39万
-
财政年份:2014
-
负责人:KEVIN C EGGAN
-
依托单位:
C9ORF72 in Motor System Biology and ALS
-
批准号:9084666
-
项目类别:
-
资助金额:$45.12万
-
财政年份:2014
-
负责人:KEVIN C EGGAN
-
依托单位:
Reprogramming using small molecules
-
批准号:8829869
-
项目类别:
-
资助金额:$31.55万
-
财政年份:2012
-
负责人:KEVIN C EGGAN
-
依托单位:
New hiPSC tools for astroglial-focused approaches to ALS
-
批准号:8293969
-
项目类别:
-
资助金额:$84.96万
-
财政年份:2012
-
负责人:KEVIN C EGGAN
-
依托单位:
Reprogramming using small molecules
-
批准号:8236158
-
项目类别:
-
资助金额:$31.42万
-
财政年份:2012
-
负责人:KEVIN C EGGAN
-
依托单位:
Generation and Characterization of Amyotrophic Lateral Sclerosis
-
批准号:8288399
-
项目类别:
-
资助金额:$84.96万
-
财政年份:2012
-
负责人:KEVIN C EGGAN
-
依托单位:
Reprogramming using small molecules
-
批准号:8448114
-
项目类别:
-
资助金额:$30.35万
-
财政年份:2012
-
负责人:KEVIN C EGGAN
-
依托单位:
Reprogramming using small molecules
-
批准号:8629767
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2012
-
负责人:KEVIN C EGGAN
-
依托单位:
Generation and Characterization of Amyotrophic Lateral Sclerosis
-
批准号:8488511
-
项目类别:
-
资助金额:$79.0万
-
财政年份:2012
-
负责人:KEVIN C EGGAN
-
依托单位:
Developmental Reprogramming after Nuclear Transfer
-
批准号:7209727
-
项目类别:
-
资助金额:$31.1万
-
财政年份:2005
-
负责人:KEVIN C EGGAN
-
依托单位:
Developmental Reprogramming after Nuclear Transfer
-
批准号:7409155
-
项目类别:
-
资助金额:$30.48万
-
财政年份:2005
-
负责人:KEVIN C EGGAN
-
依托单位:
Developmental Reprogramming after Nuclear Transfer
-
批准号:7038278
-
项目类别:
-
资助金额:$32.03万
-
财政年份:2005
-
负责人:KEVIN C EGGAN
-
依托单位:
Developmental Reprogramming after Nuclear Transfer
-
批准号:7600620
-
项目类别:
-
资助金额:$31.18万
-
财政年份:2005
-
负责人:KEVIN C EGGAN
-
依托单位:
Developmental Reprogramming after Nuclear Transfer
-
批准号:8447349
-
项目类别:
-
资助金额:$28.06万
-
财政年份:2005
-
负责人:KEVIN C EGGAN
-
依托单位:
Developmental Reprogramming after Nuclear Transfer
-
批准号:8250264
-
项目类别:
-
资助金额:$43.38万
-
财政年份:2005
-
负责人:KEVIN C EGGAN
-
依托单位:
Developmental Reprogramming after Nuclear Transfer
-
批准号:7806462
-
项目类别:
-
资助金额:$43.24万
-
财政年份:2005
-
负责人:KEVIN C EGGAN
-
依托单位:
Developmental Reprogramming after Nuclear Transfer
-
批准号:6923279
-
项目类别:
-
资助金额:$28.96万
-
财政年份:2005
-
负责人:KEVIN C EGGAN
-
依托单位:
Developmental Reprogramming after Nuclear Transfer
-
批准号:8056657
-
项目类别:
-
资助金额:$42.43万
-
财政年份:2005
-
负责人:KEVIN C EGGAN
-
依托单位:
Project 4: Dynamics of X chromosome inactivation
-
批准号:8206147
-
项目类别:
-
资助金额:$50.66万
-
财政年份:--
-
负责人:KEVIN C EGGAN
-
依托单位:
Project 4: Dynamics of X chromosome inactivation
-
批准号:8535283
-
项目类别:
-
资助金额:$40.32万
-
财政年份:--
-
负责人:KEVIN C EGGAN
-
依托单位:
海外基金